These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12403985)

  • 1. Alzheimer's disease: treatments in discovery and development.
    Citron M
    Nat Neurosci; 2002 Nov; 5 Suppl():1055-7. PubMed ID: 12403985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in Alzheimer's disease drug discovery: an update.
    Williams M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for disease modification in Alzheimer's disease.
    Citron M
    Nat Rev Neurosci; 2004 Sep; 5(9):677-85. PubMed ID: 15322526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future therapy in Alzheimer's disease.
    van Marum RJ
    Fundam Clin Pharmacol; 2008 Jun; 22(3):265-74. PubMed ID: 18485144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease.
    Hamaguchi T; Ono K; Yamada M
    Cell Mol Life Sci; 2006 Jul; 63(13):1538-52. PubMed ID: 16804637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Weksler ME; Gouras G; Relkin NR; Szabo P
    Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoprenoids and Alzheimer's disease: a complex relationship.
    Cole SL; Vassar R
    Neurobiol Dis; 2006 May; 22(2):209-22. PubMed ID: 16406223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alzheimer's disease: from brain lesions to new drugs].
    Forette F; Hauw JJ
    Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease therapeutics: new approaches to an ageing problem.
    Small DH; Losic D; Martin LL; Turner BJ; Friedhuber A; Aguilar MI
    IUBMB Life; 2004 Apr; 56(4):203-8. PubMed ID: 15230347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
    Crouch PJ; Barnham KJ; Bush AI; White AR
    Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Abeta production by NF-kappaB inhibitors.
    Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
    Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
    Stock N; Munoz B; Wrigley JD; Shearman MS; Beher D; Peachey J; Williamson TL; Bain G; Chen W; Jiang X; St-Jacques R; Prasit P
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2219-23. PubMed ID: 16455248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease.
    Hussain I
    IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evoking plasmin for beta-amyloid clearance.
    Zhao J; Pei G
    Cell Res; 2008 Aug; 18(8):803-4. PubMed ID: 18679173
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease.
    Vardy ER; Catto AJ; Hooper NM
    Trends Mol Med; 2005 Oct; 11(10):464-72. PubMed ID: 16153892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
    Citron M
    Trends Pharmacol Sci; 2004 Feb; 25(2):92-7. PubMed ID: 15102495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.